No Data
No Data
Insiders the Biggest Winners as Shijiazhuang Yiling Pharmaceutical Co., Ltd.'s (SZSE:002603) Market Cap Rises to CN¥26b
Key Insights Significant insider control over Shijiazhuang Yiling Pharmaceutical implies vested interests in company growth The top 2 shareholders own 52% of the company Using data from analyst
Shijiazhuang Yiling Pharmaceutical: 2024 Interim Performance Forecast
Shijiazhuang Yiling Pharmaceutical (002603.SZ): Received the Drug Registration Application Acceptance Notice for Benamorphene Injection.
On July 10th, Gelonhui reported that Yiling Pharmaceuticals (002603.SZ) has received the "Acceptance Notice" issued by the National Medical Products Administration, and the new drug registration application for "benzamide propyphenazone injection" submitted by the company has been formally accepted. Benzamide propyphenazone injection is a new chemical drug independently developed by the company. Benzamide propyphenazone injection belongs to the class of arylalkanoic acid analgesic and anti-inflammatory drugs in its chemical structure, which can inhibit the synthesis of prostaglandins and exert analgesic and anti-inflammatory effects by blocking inflammatory mediators. Its clinical indications include: postoperative mild to moderate pain in adults, and combined with opioid analgesics for the treatment of moderate to severe pain after surgery.
Express News | Shijiazhuang Yiling Pharmaceutical Says It Sees H1 Net Profit Down 60-73% Y/Y
The Five-year Decline in Earnings for Shijiazhuang Yiling Pharmaceutical SZSE:002603) Isn't Encouraging, but Shareholders Are Still up 116% Over That Period
Shijiazhuang Yiling Pharmaceutical Co., Ltd. (SZSE:002603) shareholders might be concerned after seeing the share price drop 21% in the last quarter. But that doesn't change the fact that the retur
Shijiazhuang Yiling Pharmaceutical (002603.SZ): The new drug registration application for Beijing Yiling's "Chaihu Li Dan Capsule" has been accepted.
On June 13th, Gelunhui reported that Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603.SZ) announced that its wholly-owned subsidiary, Beijing Yiling Pharmaceutical Co., Ltd. (referred to as 'Beijing Yiling'), received the 'Acceptance Notification' issued by the National Medical Products Administration. The registration application for the new drug 'Chaihuang Lidong Capsules' submitted by Beijing Yiling has been formally accepted. Chaihuang Lidong Capsules is a traditional Chinese medicine innovative drug independently developed by the company. Its functions are to clear heat and dampness, regulate liver and gallbladder, and soothe the stomach and relieve pain. It is used for chronic cholecystitis, liver and gallbladder damp heat, gastric loss and descent syndrome, with symptoms such as discomfort or pain in the upper right abdomen, bitter mouth and dry throat upon waking up in the morning.
No Data